AEON BIOTECH AS: årsregnskap 2025 vs 2024
Shrank 89% on revenue, stronger earnings, cash halved-plus
approved 2026-05-25; registry 2026-06-02; journal 2026 506340
Summary
What changed
Comparing Årsregnskap 2025 with 2024 for AEON BIOTECH AS. Revenue 113.0k NOK → 12.0k NOK (-89.4%). Net result -207.2k NOK → -59.9k NOK. Equity -131.4k NOK → -441.3k NOK.
On the constructive side: operating result improved; net result improved. Pressures included: revenue fell; equity eroded; cash fell.
Also worth watching: thin equity buffer; paid-in equity reduced; cogs fell. All figures are taken from the published annual accounts for AEON BIOTECH AS.
At a glance
Scorecard
What improved
-
↑
Operating result improved
Operating result -206.9k NOK → -59.9k NOK (op. margin -183.1% → -500.0%). Calculated
-
↑
Net result improved
Net result -207.2k NOK → -59.9k NOK (net margin -183.3% → -500.0%). Calculated
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 113.0k NOK to 12.0k NOK (-89.4% YoY). Calculated
-
↓
Equity eroded
Book equity -131.4k NOK → -441.3k NOK (equity ratio -362.1% → -20986.0%). Calculated
-
↓
Cash fell
Bank deposits 4 965 NOK → 2 103 NOK (-57.6% YoY). Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is -20986.0% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation
-
·
Paid-in equity reduced
Paid-in equity fell 744.4k NOK → 494.4k NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
COGS fell
COGS / varekostnad 247.3k NOK → 247 NOK (-99.9% YoY). Calculated